Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
MDA-MB-134-VI INK-128
3.1623
mTORC1/2
PI3K/mTOR
 -0.8853 0.52609
MDA-MB-361 Luminespib
0.31623
HSP90
Misc
 -0.8812 0.73884
HCC70 Ceritinib
10.0
ALK
RTK
 -0.8808 0.51303
HCC70 Dinaciclib
0.31623
pan CDK
Cell cycle
 -0.8802 0.72250
MDA-MB-134-VI ABT-737
10.0
Bcl2/XL
Misc
 -0.8735 0.56669
MDA-MB-361 Luminespib
0.1
HSP90
Misc
 -0.8712 0.72786
HCC70 Dinaciclib
0.031623
pan CDK
Cell cycle
 -0.8675 0.69990
HCC1428 Ceritinib
10.0
ALK
RTK
 -0.8673 0.83636
HCC1419 Ceritinib
10.0
ALK
RTK
 -0.8670 0.78048
HCC70 Topotecan
10.0
Topo I
Chemotherapy
 -0.8614 0.69928
MDA-MB-157 Dinaciclib
0.1
pan CDK
Cell cycle
 -0.8610 0.78558
MDA-MB-134-VI Torin2
0.31623
mTOR/ATM/ATR
PI3K/mTOR
 -0.8587 0.52277
MDA-MB-361 Taselisib
1.0
PI3Ka, g, d
PI3K/mTOR
 -0.8577 0.70554
T47D Ceritinib
10.0
ALK
RTK
 -0.8550 0.88984
MDA-MB-361 Luminespib
0.031623
HSP90
Misc
 -0.8543 0.71039
PDX1328 Cediranib
10.0
VEGFR/cKIT
RTK
 -0.8534 0.62581
MDA-MB-361 INK-128
3.1623
mTORC1/2
PI3K/mTOR
 -0.8457 0.67173
MDA-MB-134-VI Dinaciclib
1.0
pan CDK
Cell cycle
 -0.8440 0.50908
MDA-MB-134-VI Doxorubicin
0.31623
Chemo
Chemotherapy
 -0.8349 0.47478
MDA-MB-157 Topotecan
10.0
Topo I
Chemotherapy
 -0.8333 0.60008
MDA-MB-134-VI INK-128
1.0
mTORC1/2
PI3K/mTOR
 -0.8266 0.46397
HCC70 Abemaciclib
10.0
CDK4/6
Cell cycle
 -0.8264 0.64288
HCC70 Topotecan
3.1623
Topo I
Chemotherapy
 -0.8255 0.70800
SK-BR-3 Ceritinib
10.0
ALK
RTK
 -0.8254 0.74759
MDA-MB-134-VI Buparlisib
10.0
pan PI3K
PI3K/mTOR
 -0.8251 0.46691